
Advancing scientific knowledge

Our Company

Our Science


Our Pipeline

Recent Data Presentations
Explore the latest research from our scientists
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/
Refractory Diffuse Large B-Cell Lymphoma
Caimi PF, Ai W, Alderuccio JP, et al.
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Linhares Y, Gandhi M, Chung M, et al.
Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
Depaus J, Wagner-Johnston ND, Zinzani PL, et al.
Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Spira AI, Chen L, Zhou X, et al.
Characteristics and Treatment Patterns of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies
Xie J, Wu A, Liao L, et al.
Analysis of ADCT-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity
Gaudio E, Tarantelli C, Cascione L, et al.
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
Herrera AF, Carlo-Stella C, Collins GP, et al.
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, With Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Jabeen A, Huang S, Hartley JA, et al.
Pharmacokinetic and Pharmacodynamic Correlates From the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Boni J, Havenith K, Hamadani M, et al.




MedConnect
Real-time answers to your pressing questions
Our Company
Driven by our dedication to improving outcomes in difficult-to-treat cancers, we are leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.Watch a short video to learn more about our company (2:05)
Our Science
Advancing antibody drug conjugates with a novel class of PBD dimersADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD-dimer toxins.PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA. Unlike earlier generation PBD chemistry, ADC Therapeutics’ proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.Our PBD-dimer technology: A novel approach to hematologic cancers and solid tumors

-
1The antigen-targeted antibody binds to a specific tumor cell surface antigen and internalizes the drug conjugate
-
2The potent PBD dimer is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix
-
3Because these cross links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death
Watch an MOA video of our lead ADC candidate, Lonca (2:32)
Our Pipeline
A robust pipeline of investigational ADCs for the treatment of hematological cancers and solid tumorsADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.

Expand each compound to learn more.
Learn more about our pipeline Watch a video tour of the LOTIS Clinical Development Program (3:00)
Recent Data Presentations
Explore the latest research from our scientists